Atopic dermatitis or atopic eczema is a chronic, relapsing, familial, symmetric and pruritic inflammatory skin disease that commonly presents during early infancy and childhood, but can persist or start in adulthood.
It is commonly associated with elevated serum immunoglobulin E levels and a personal or family history of allergies, allergic rhinitis and asthma.
It is one of the most common skin diseases afflicting both children and adults.
A 300 mg QW or Q2W maintenance dupilumab regimen is less likely to result in worsening of atopic dermatitis (AD) than switching to a Q4W or Q8W regimen, results of the phase III LIBERTY AD SOLO-CONTINUE* trial show.
In clinical trials of systemic therapy in atopic dermatitis (AD), the integration of double- and triple-blinding can lower placebo responses, according to the results of a systematic review and meta-analysis. Other means of achieving this include balancing of patient sex distribution, disallowing concomitant use of prescription topical therapy and having shorter study durations.
Patients with moderate-to-severe atopic dermatitis (AD) were more likely to have clinically meaningful responses when treated with dupilumab at doses of 300 mg either weekly or every 2 weeks compared with those on placebo, according to a post hoc analysis of the phase III SOLO 1 and SOLO 2* trials presented as a poster at AAD 2019.
Current evidence shows dupilumab and cyclosporine as effective treatment for severe atopic dermatitis (AD), reports a recent systematic review, adding that long-term safety and efficacy of biologic medications require further research.
Two novel investigational topical agents show potential in improving symptoms of atopic dermatitis, according to early phase trials presented at the Inflammatory Skin Disease Summit (ISDS) in Vienna, Austria.
Acidity of the skin appears to be significantly higher in atopic dermatitis (AD) patients than in controls without the condition, indicating that increased skin pH may heighten the risk of developing AD, according to a study.
Most clinical guidelines recommend daily bathing in lukewarm water, followed by the application of moisturizers, in the treatment of atopic dermatitis (AD), according to an expert who presented at the 23rd Asian-Australasian Regional Conference of Dermatology (RCD 2018) held in Surabaya, Indonesia.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.